VERV
Verve Therapeutics Inc. (acquired by Eli Lilly; no VERV listing)
Is VERV Halal?
Eli Lilly completed Verve's acquisition in July 2025 and VERV was delisted; the gene-editing qualitative analysis is retained without fabricating current standalone ratios.
What You Should Know
VERV is a preserved Verve Therapeutics route. Eli Lilly completed its acquisition in July 2025, and Verve's common stock was delisted and deregistered. Therapeutic genetic-medicine research remains the qualitative subject, including the preventative-versus-therapeutic and bioethics questions; a current standalone VERV quantitative screen is not applicable.
⚠️ Concerns
- •VERV was acquired and delisted in July 2025
- •Preventative versus therapeutic gene editing
- •Clinical-trial materials and bioethics
- •VERV is a preserved Lilly-acquisition alias; the URL is unchanged
Current quantitative Sharia screen
Based on issuer-status figures for the period ended 2025-07-24; calculated 2026-07-15.
- Financial
- Not calculated
- Overall
- Not calculated
Not calculated because VERV was acquired and delisted in July 2025.
- Financial
- Not calculated
- Overall
- Not calculated
No current standalone Verve financial statement is available.
- Financial
- Not calculated
- Overall
- Not calculated
Not calculated for the delisted VERV security.
- Financial
- Not calculated
- Overall
- Not calculated
VERV has no current public-market price or market-cap series.
Business-activity disclosure
Verve historically developed genetic medicines for cardiovascular disease. Therapeutic research is generally permissible in principle, while gene-editing, clinical-material and product-use questions remain qualitative; VERV is no longer a public security.
Limitation: No current standalone Verve balance sheet, revenue statement or public share price exists after the Lilly acquisition.
Purification
No current standalone VERV issuer income is available for purification.
Inputs, assumptions and primary sources
- Eli Lilly completed its acquisition of Verve in July 2025; the VERV common stock was delisted and deregistered.
- No current Lilly segment figures are substituted for a standalone VERV screen, so numerical ratios are intentionally not calculated.
- The URL and existing qualitative gene-editing analysis are preserved.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →